Agenus (AGEN) to Release Quarterly Earnings on Tuesday

Agenus (NASDAQ:AGEN) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($3.10) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The firm had revenue of $83.80 million for the quarter, compared to analysts’ expectations of $54.21 million. On average, analysts expect Agenus to post $-8 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Agenus Price Performance

NASDAQ:AGEN opened at $13.07 on Monday. The firm has a market cap of $265.06 million, a price-to-earnings ratio of -0.92 and a beta of 1.25. The company has a 50 day moving average price of $10.88 and a 200-day moving average price of $13.32. Agenus has a 1-year low of $4.78 and a 1-year high of $42.60.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AGEN. B. Riley cut their target price on shares of Agenus from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, March 18th. StockNews.com started coverage on shares of Agenus in a report on Wednesday, April 17th. They issued a “hold” rating for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $160.00 price target on shares of Agenus in a report on Thursday, March 14th.

Insiders Place Their Bets

In other Agenus news, insider Garo H. Armen bought 25,000 shares of the stock in a transaction on Thursday, February 15th. The shares were bought at an average price of $13.00 per share, with a total value of $325,000.00. Following the purchase, the insider now directly owns 31,298 shares in the company, valued at approximately $406,874. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.80% of the stock is currently owned by corporate insiders.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.